• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 2:51:40 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APVO alert in real time by email
    SC 13G/A 1 d8805025_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Aptevo Therapeutics Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    03835L207
    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     


    CUSIP No
    03835L207    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Armistice Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0    
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0    
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0    
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA, OO  
     
     

     

    CUSIP No 03835L207    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Steven Boyd  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0    
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0    
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0    
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  
     
     

     


    CUSIP No
    03835L207    

     

           
    Item 1. (a). Name of Issuer:  
           
        Aptevo Therapeutics Inc.  
           
      (b). Address of Issuer's Principal Executive Offices:  
           
       

    2401 4th Avenue, Suite 1050

    Seattle, Washington 98121

    United States of America

     
           
           
    Item 2. (a). Name of Person Filing:  
           
       

    Armistice Capital, LLC

    Steven Boyd

     
           
      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     
           
      (c) Citizenship:  
           
       

    Armistice Capital, LLC – Delaware

    Steven Boyd – United States of America

     
           
      (d).   Title of Class of Securities:  
           
        Common Stock, par value $0.001 per share  
     

     

     

       
      (e). CUSIP Number:  
           
        03835L207  

     


    Item 3.
      If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
           
      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

     

     
    Item 4. Ownership.
     
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)   Amount beneficially owned:
         
       

    Armistice Capital, LLC – 0

    Steven Boyd – 0

         
      (b)   Percent of class:
         
       

    Armistice Capital, LLC – 0%

    Steven Boyd – 0%

         

     

      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     

     
        (ii)   Shared power to vote or to direct the vote    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     

     
        (iii) Sole power to dispose or to direct the disposition of    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     

     
        (iv)   Shared power to dispose or to direct the disposition of    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     
                 

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      An advisory client of Armistice Capital, LLC, has the right to receive dividends from, and the proceeds from the sale of, the reported securities.
       

     

     
     

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      February 16, 2021
      (Date)

     

     

      Armistice Capital, LLC
       
      By:  /s/ Steven Boyd
      Steven Boyd
      Managing Member
     

     

     

      /s/ Steven Boyd
      Steven Boyd

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

     

    Exhibit A

    AGREEMENT

     

    The undersigned agree that this Amendment No. 2 to Schedule 13G dated February 16, 2021 relating to the Common Stock, par value $0.001 per share, of Aptevo Therapeutics Inc. shall be filed on behalf of the undersigned.

      Armistice Capital, LLC
       
      By:  /s/ Steven Boyd
      Steven Boyd
      Managing Member
     

     

     

      /s/ Steven Boyd
      Steven Boyd

     

      

     

     

     

    Get the next $APVO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APVO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Aptevo Therapeutics Inc.

      SCHEDULE 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

      7/8/25 2:11:55 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aptevo Therapeutics Inc.

      DEF 14A - Aptevo Therapeutics Inc. (0001671584) (Filer)

      7/7/25 12:11:40 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptevo Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)

      7/1/25 5:05:48 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Huebner Dirk claimed no ownership of stock in the company (SEC Form 3)

      3 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      7/9/25 5:32:20 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, GC, BD & Corp Affairs Kwon Soyoung converted options into 4 shares, increasing direct ownership by 19% to 25 units (SEC Form 4)

      4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      3/4/25 4:36:04 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, COO Lamothe Jeffrey G. converted options into 5 shares, increasing direct ownership by 16% to 36 units (SEC Form 4)

      4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      3/4/25 4:35:19 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Aptevo Therapeutics with a new price target

      Roth Capital reiterated coverage of Aptevo Therapeutics with a rating of Buy and set a new price target of $50.00 from $64.00 previously

      5/28/21 8:33:45 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

      Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today.DetailsSession Title: Bi and Multispecific BiologicsTalk Title: Modular Multispecific

      1/15/25 8:00:00 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

      SEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common s

      12/12/24 12:50:00 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

      Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing mipletamig trialCohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual d

      12/12/24 9:00:00 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aptevo Therapeutics Inc.

      SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

      11/14/24 3:45:38 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aptevo Therapeutics Inc.

      SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

      11/8/24 2:57:35 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aptevo Therapeutics Inc.

      SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

      2/14/24 3:24:02 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Leadership Updates

    Live Leadership Updates

    See more
    • BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

      NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

      11/2/21 9:00:00 AM ET
      $AMGN
      $APVO
      $BCTX
      $BMY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations